UGT2B15 Poor Metabolism and Lisinopril: No Clinical Interaction
UGT2B15 poor metabolism has no clinically relevant impact on lisinopril therapy, as lisinopril is not metabolized by UGT enzymes or any hepatic pathway—it is excreted unchanged exclusively by the kidneys.
Lisinopril Metabolism and Elimination
Lisinopril does not undergo hepatic metabolism of any kind:
- Lisinopril is absorbed in its active form and excreted completely unchanged in the urine, with no measurable metabolism occurring in the body 1, 2, 3
- Approximately 25-29% oral bioavailability, with renal excretion as the sole elimination pathway 1, 2
- The elimination half-life is 12.6 hours in patients with normal renal function 2
Why UGT2B15 Status is Irrelevant
UGT2B15 is a phase II conjugation enzyme involved in glucuronidation of certain drugs and endogenous compounds. Since lisinopril:
- Requires no hepatic activation or metabolism 1, 2
- Is not a substrate for any cytochrome P450 enzymes
- Is not conjugated by UGT enzymes
- Undergoes zero biotransformation before renal excretion 3
Poor, intermediate, or extensive UGT2B15 metabolizer status has absolutely no bearing on lisinopril pharmacokinetics, efficacy, or safety.
What Actually Matters for Lisinopril Dosing
Renal Function is the Critical Factor
- Significant drug accumulation occurs only when creatinine clearance falls below 30 mL/min 1, 4
- Initial dosing should be 2.5 mg daily when GFR <30 mL/min, and 5 mg daily for GFR 30-60 mL/min 4, 5
- Steady state is achieved in 2-3 days with normal renal function, but accumulation occurs with severe renal impairment 1
Standard Monitoring Parameters
The American College of Cardiology and American Heart Association recommend:
- Check serum creatinine and potassium within 2-4 weeks of initiation or dose increase 6, 7
- Accept up to 10-20% increase in serum creatinine as expected pharmacodynamic effect 6, 8
- Monitor for hyperkalemia, particularly in patients with baseline renal impairment 9, 5
Evidence-Based Dosing Strategy
For cardiovascular indications with proven mortality benefit:
- Start lisinopril at 2.5-5 mg once daily and titrate to target dose of 20-40 mg once daily 7, 8
- High-dose lisinopril (32.5-35 mg/day) demonstrated significantly lower mortality compared to low-dose (2.5-5 mg/day) in the ATLAS trial 10, 7
- Titrate doses every 1-2 weeks based on blood pressure response and tolerance 7, 8
Clinical Bottom Line
No dose adjustment, special monitoring, or therapeutic concern exists for patients with UGT2B15 poor metabolism taking lisinopril. Focus clinical attention on renal function monitoring, potassium levels, and blood pressure response—these are the only factors that influence lisinopril therapy 6, 1, 4.